Outlook Therapeutics (OTLK) EBITDA (2015 - 2026)

Outlook Therapeutics (OTLK) has reported EBITDA for 12 consecutive years, with -$10.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 31.36% year-over-year to -$10.8 million in Q2 2026; TTM through Jun 2026 was -$55.6 million, a 23.39% increase from a year earlier, with the FY2025 full-year figure at -$67.1 million, up 6.47% from the prior year.
• EBITDA was -$10.8 million for Q2 2026 at Outlook Therapeutics, up from -$14.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$6.8 million in Q1 2023 and troughed at -$22.9 million in Q3 2024.
• A 5-year average of -$15.6 million and a median of -$15.7 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 63.84% in 2023 and plunged 176.98% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$15.7 million in 2022, then jumped by 34.2% to -$10.3 million in 2023, then plunged by 109.31% to -$21.6 million in 2024, then jumped by 37.59% to -$13.5 million in 2025, then advanced by 19.83% to -$10.8 million in 2026.
• The last three EBITDA figures came in at -$10.8 million (Q2 2026), -$14.0 million (Q1 2026), and -$13.5 million (Q4 2025), per Business Quant data.